An Adaptive Phase II/III, Double-Blind, Randomized, Placebo-controlled, Two-Part, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®,a D-Amino Acid Oxidase Inhibitor, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

Trial Profile

An Adaptive Phase II/III, Double-Blind, Randomized, Placebo-controlled, Two-Part, Dose-Finding, Multi-center Study of the Safety and Efficacy of NaBen®,a D-Amino Acid Oxidase Inhibitor, as an Add-on Therapy With Clozapine, for Residual Symptoms of Refractory Schizophrenia in Adults

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 22 May 2017

At a glance

  • Drugs Sodium benzoate (Primary) ; Clozapine
  • Indications Schizophrenia
  • Focus Therapeutic Use
  • Sponsors SyneuRx International (Taiwan) corp
  • Most Recent Events

    • 22 May 2017 According to a SyneuRx International media release, this study has been granted by the US FDA with both Orphan Drug Designation (ODD) and Breakthrough Therapy Designation (BTD). The first five patients have been randomized in this trial.
    • 06 Apr 2017 Status changed from not yet recruiting to recruiting.
    • 31 Mar 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top